Kurz gefasst
Fachartikel in der Zeitschrift Drugs, online erschienen am 17.11.2026. Verfasst von Yahiya Y Syed. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Daraxonrasib (RASONQUE™) is an oral, multiselective, noncovalent RAS(ON) inhibitor being developed by Revolution Medicines for the treatment of solid tumours, including pancreatic ductal adenocarcinoma (PDAC), non-small-cell lung cancer and colorectal cancer. Daraxonrasib received its first approval in the USA on 26 August 2026 for the treatment of adults with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. This article summarizes the milestones in the development of daraxonrasib leading to its first approval for metastatic PDAC.
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Syed, Y. Y. (2026). Daraxonrasib: First Approval. Drugs. https://doi.org/10.1007/s40265-026-02414-x
Vancouver
Syed YY. Daraxonrasib: First Approval. Drugs. 2026. doi:10.1007/s40265-026-02414-x
BibTeX
@article{Syed2026,
author = {Syed, Yahiya Y},
title = {Daraxonrasib: First Approval},
journal = {Drugs},
year = {2026},
doi = {10.1007/s40265-026-02414-x}
}
EUVIMED